Keywords: s-p, begins, ph, iii, vicriviroc, trials, drugmaker
S-P begins two Ph III vicriviroc trials
Article | 24 September 2007
US drugmaker Schering-Plough has initiated two Phase III clinical studies of vicriviroc, its once-daily, next-generation CCR5 anatgonist, which is being ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
